Sparta

Progenra, Inc., located in Malvern, PA, is dedicated to discovering and developing novel first-in-class medicines by leveraging its expertise in the ubiquitin-proteasome system, Molecular Glues, and PROTAC drug technologies. The company focuses on addressing unmet medical needs across a spectrum of therapeutic areas, including cancer and neurodegenerative diseases such as Parkinson's disease. Through collaborations and innovative research initiatives, Progenra aims to advance drug discovery and improve therapeutic outcomes by targeting the ubiquitin-proteasome system. Their commitment to developing KRAS degraders for cancer therapy exemplifies their leadership in the field of ubiquitin drug discovery. Generated from the website